William Maughan
Stock Analyst at Canaccord Genuity
(3.38)
# 1,086
Out of 4,424 analysts
7
Total ratings
50%
Success rate
23.72%
Average return
Main Sectors:
Top Industries:
5 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| YMAB Y-mAbs Therapeutics | Maintains: Buy | $20 → $18 | $12.28 | +46.58% | 2 | Mar 31, 2023 | |
| XNCR Xencor | Maintains: Buy | $48 → $42 | $22.48 | +86.83% | 2 | Feb 24, 2023 | |
| OLMA Olema Pharmaceuticals | Assumes: Buy | $16 | $9.32 | +71.67% | 1 | Jul 6, 2022 | |
| BNTX BioNTech SE | Assumes: Buy | $192 | $91.67 | +109.45% | 1 | Jul 6, 2022 | |
| BCYC Bicycle Therapeutics | Assumes: Buy | $60 | $22.89 | +162.12% | 1 | Jul 6, 2022 |
Y-mAbs Therapeutics
Mar 31, 2023
Maintains: Buy
Price Target: $20 → $18
Current: $12.28
Upside: +46.58%
Xencor
Feb 24, 2023
Maintains: Buy
Price Target: $48 → $42
Current: $22.48
Upside: +86.83%
Olema Pharmaceuticals
Jul 6, 2022
Assumes: Buy
Price Target: $16
Current: $9.32
Upside: +71.67%
BioNTech SE
Jul 6, 2022
Assumes: Buy
Price Target: $192
Current: $91.67
Upside: +109.45%
Bicycle Therapeutics
Jul 6, 2022
Assumes: Buy
Price Target: $60
Current: $22.89
Upside: +162.12%